Increase in serum concentrations of IgG₂ and IgG₄ by selenium supplementation in children with Down's syndrome

G Annerén, C G M Magnusson, S L Nordvall

Abstract
In a previous study on children with Down's syndrome a reduced rate of infections was reported by their parents after the children had received six months' treatment with selenium supplements. In the present study the concentrations of the four IgG subclasses were measured in 29 of these children in samples of serum obtained before and immediately after the period of supplementation and one year after it had finished. Selenium had a significant augmentative effect on the serum concentrations of IgG₂ and IgG₄, but not of IgG₁ and IgG₃. This effect was not related to age, as among children over the age of 6 years the serum concentrations of IgG₂ and IgG₄ had decreased significantly one year after the treatment had been stopped. This study suggests that selenium has an immunoregulatory effect, which might be of importance in both basic research and clinical practice.

Susceptibility to infections is a feature of Down's syndrome and is likely to be caused by abnormalities in host defence—for example, in the immune response. In patients with Down's syndrome the serum concentration of IgG₄ is either normal or slightly raised. The serum concentrations of the IgG₂ and IgG₄ subclasses are significantly reduced, and those of IgG₃ and IgG₁ are normal or increased in both adults' and children with Down's syndrome (G Annerén et al, unpublished observations). In a study of six months' selenium supplementation in children with Down's syndrome that was designed to investigate the effect on the activity of glutathione peroxidase in erythrocytes and on the concentrations of selenium in the plasma and erythrocytes, many of the parents spontaneously reported a reduced rate of infections among their children after treatment with selenium.

Older patients with Down's syndrome tend to develop a presenile dementia that has striking similarities to Alzheimer's disease. It has been suggested that this might be due to increased lipid peroxidation as a secondary gene dosage effect of the 50% increase in the activity of superoxide dismutase in trisomy 21 cells. The rationale for selenium supplementation was to find out whether the activity of the selenium dependent enzyme glutathione peroxidase would increase and improve the protection against oxygen radicals.

The aim of the present study was to investigate whether the reported decrease in infections could be related to a change in the serum pattern of IgG subclasses among children with Down's syndrome.

Patients and methods
In the previous study 48 children with Down's syndrome, verified by chromosomal analysis, who were living at home were enrolled. Selenium was given as selenium rich yeast tablets (Novamed Selen, Huhtamäki OY) in a dose of 10 μg/kg body weight/day for six months. The children were examined clinically before and immediately after the six month supplementation period, and again one year later. On each of these three occasions a sample of serum was collected and stored at −20°C until it was analysed. The plasma and erythrocyte selenium concentrations increased roughly fourfold during the period of supplementation and had almost regained the pretreatment concentrations one year after withdrawal. Sufficient volumes of serum for the present study were available from 29 of the 48 children: 19 boys and 10 girls, aged 1-5 to 15 years.

The serum concentrations of the four subclasses of IgG were determined by a competitive two step microtitre enzyme linked immunosorbent assay (ELISA) based on subclass specific monoclonal antibodies and rabbit antinmouse immunoglobulin antibodies conjugated to alkaline phosphatase. The assay conditions regarding the buffers used, incubation times, sample dilutions and the evaluation of specificity, sensitivity, linearity, precision and accuracy will be described in detail elsewhere (C G M Magnusson, unpublished observations). All three serum samples from each patient were assayed in duplicate on the same plate to minimize intra-subject variations. A commercial standard serum (H00-03, Janssen, Belgium), calibrated against the World Health Organisation 67/97 standard, was used to produce standard curves. Interassay imprecision, which was evaluated by including two dilutions of a control serum on each plate, gave coefficients of variation on seven different plates of 4-9% for IgG₁, 5-8% for IgG₂, 5-1% for IgG₃, and 8-9% for IgG₄. Undetectable IgG₄ (<5 mg/l) was assigned a value of 2·5 mg/l.

Statistical analysis was by Wilcoxon's signed rank test. Because of the age dependence of IgG subclass concentrations, the children were split into two age groups, ≤6 (n=13) and >6 years (n=16), for the statistical analyses.

Results
After a six month period of selenium supple-
Discussion
In this study selenium supplementation was found to have an augmentative effect on the serum concentrations of IgG2 and IgG4 in children with Down's syndrome, which is of particular interest because concentrations of these two subclasses are low in patients with Down's syndrome (G Annerén et al., unpublished observations). Although no control group was included the data seem convincing because both the IgG2 and IgG4 concentrations declined significantly during the year after withdrawal of supplementation among children >6 years. A corresponding decrease in the younger age group was probably masked by an expected rise in these subclasses with age. To our knowledge this is the first study showing a linkage between selenium treatment and immunological host defence in man.

Children with Down's syndrome are especially prone to respiratory bacterial infections. This may be partly explained by a deficiency in IgG4, and IgG2 antibodies, of which the latter are known to be directed against bacterial polysaccharide antigens of encapsulated bacteria such as Streptococcus pneumoniae and Haemophilus influenzae. The effect of selenium serum IgG2 and IgG4 concentrations may therefore be of clinical importance and in some way related to the spontaneously reported reduced rate of infections among the children with Down's syndrome. We are unable to present trustworthy clinical correlates to our laboratory data, however, as the original study was not designed for this purpose. It also remains to be investigated whether the observed effects upon IgG2 and IgG4 are confined to patients with Down's syndrome alone.

Our limited knowledge about the biological role of selenium is partly because selenium defi-
Increase in serum concentrations of IgG2 and IgG4 by selenium supplementation in children with Down's syndrome